UK Markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
53.10+1.76 (+3.42%)
At close: 06:00PM BST
Full screen
Previous close51.35
Open52.80
Bid0.00 x 0
Ask0.00 x 0
Day's range52.70 - 53.10
52-week range52.70 - 53.10
Volume1,257
Avg. volumeN/A
Market cap782.274M
Beta (5Y monthly)0.99
PE ratio (TTM)N/A
EPS (TTM)-0.76
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA

    Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousCOSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA 03.05.2022 / 06:00 Press Release (PDF)Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.Eleview(R) is a sub

  • EQS Group

    COSMO ANNOUNCES FULL-YEAR RESULTS 2021;CONFIRMS BEATING GUIDANCE

    Cosmo Pharmaceuticals N.V. / Key word(s): Annual Results23-March-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.9

  • EQS Group

    First U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with Artificial Intelligence (AI) technology versus standard colonoscopy

    Cosmo Pharmaceuticals N.V. / Key word(s): Study results18-March-2022 / 06:01 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland - 18 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announced that Medtronic on 16 March 2022 issued the following release:Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, intern